Poly (D,L-lactide-co-glycolide) nanoparticles: Uptake by epithelial cells and cytotoxicity

Nkabinde, Lindiwe A.; Shoba-Zikhali, L. N. N.; Semete-Makokotlela, Boitumelo; Kalombo, Lonji; Swai, Hulda; Grobler, Anne; Hamman, Josias H.

doi:10.3144/expresspolymlett.2014.23

Cited by 16 publications

(15 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among several options, poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and poly(lactic acid‐co‐glycolic acid) (PLGA) are approved by the FDA as useful matrices for DDS applications due to their known biocompatibility and biodegradability . More specifically, PLGA is extensively used in drug delivery systems (DDS) as alternative to improve conventional formulations, mainly by releasing the drug molecules in a controlled manner over long time from a single shot.…”

Section: Introductionmentioning

confidence: 99%

Quantification of Oxaliplatin Encapsulated into PLGA Microspheres by TGA

Sáez

Cerruti

Ramón

et al. 2016

Macromolecular Symposia

View full text Add to dashboard Cite

Summary Oxaliplatin (OP) is an anti‐tumor agent used for advanced colorectal cancer treatment. Therapies with OP produce side effects, which could be reduced by its encapsulation into PLGA microspheres (MS). The determination of OP content in MS is important for defining the exact quantity of loaded particles into final formulation and achieve correct dosage of this drug. This research focuses on determining OP through the Pt residue which is quantified by thermogravimetric analysis (TGA). It was demonstrated that there is no significant difference between the intrinsic residues for MS obtained with the PLA or PLGA. In turn, a statistically significant difference was detected between residue of tested polymers. The linearity was proved (R2 = 0.9998) by evaluating samples prepared from mixtures of empty PLGA MS and known quantities of OP. The detection limit was equal to 0.25% Pt residue while the quantitation limit was equal to 0.78%. Thus, TGA allows to quantify oxaliplatin loadings as small as 1.57 wt% in samples of 20 mg.

show abstract

Section: Introductionmentioning

confidence: 99%

Quantification of Oxaliplatin Encapsulated into PLGA Microspheres by TGA

Sáez

Cerruti

Ramón

et al. 2016

Macromolecular Symposia

View full text Add to dashboard Cite

show abstract

“…Consequently, it may diminish side effects caused by high concentrations and repeated administrations, and improve patient compliance as compared to conventional regimens [20] . Poly(lactic-co-glycolic acid) (PLGA) copolymers [21] have been extensively used in drug delivery systems (DDS) as alternative to improve conventional formulations [21][22][23] . These DDSs allow extended and controlled releases of drugs dispersed into the polymer [24] .…”

Section: Introductionmentioning

confidence: 99%

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

et al. 2016

View full text Add to dashboard Cite

SbstractOxaliplatin was inserted into polymeric matrices aiming to study the interaction of this drug with these polymers and its capability to diffuse to the environment. Tested polymers were: (1) polyethylene glycol (PEG), (2) poly(lactic-co-glycolic acid) (PLGA), and (3) a copolymer of them (PLGA-PEG). The latter two were synthesized by us using polycondensation in bulk. Oxaliplatin was included in the matrices by the melt mixing process followed by casting. Fourier tran sform infrared spectroscopy (FTIR), proton nuclear magnetic resonance ( 1 H-NMR) and X-ray diffraction (DRX) studies of the polymers were performed proving the obtaining of the desired materials. In addition, the interaction between drug and matrices and the release profile of the oxaliplatin from these matrices were analyzed. Among them, PEG did not control the oxaliplatin release. In turn, PLGA and PLGA-PEG present drug release profiles quite similar. Oxaliplatin was completely released from PLGA and PLGA-PEG in 5 hours, by a relaxation mechanism. There was no evidence of oxaliplatin interaction with the different polymers. In addition, as the PEG improves the biocompatibility and biomasking, obtained results prove the obtaining of a drug release system, which allowed the total use of the drug improving the cancer treatment and even the welfare of the patients.

show abstract

“…This finding corroborates that PPAA/PLGA blended MPs cause no significant cell toxicity under these conditions. These results are in agreement with others who have reported that particulate formulations containing PLGA have negligible toxicity in vitro …”

Section: Resultsmentioning

confidence: 99%

Formulation and characterization of poly(propylacrylic acid)/poly(lactic‐co‐glycolic acid) blend microparticles for pH‐dependent membrane disruption and cytosolic delivery

Fernando

Lewis

Evans

et al. 2017

J Biomedical Materials Res

View full text Add to dashboard Cite

Poly(lactic-co-glycolic acid) (PLGA) is widely used as a vehicle for delivery of pharmaceutically relevant payloads. PLGA is readily fabricated as a nano- or microparticle (MP) matrix to load both hydrophobic and hydrophilic small molecular drugs as well as biomacromolecules such as nucleic acids and proteins. However, targeting such payloads to the cell cytosol is often limited by MP entrapment and degradation within acidic endolysosomes. Poly(propylacrylic acid) (PPAA) is a polyelectrolyte polymer with the membrane disruptive capability triggered at low pH. PPAA has been previously formulated in various carrier configurations to enable cytosolic payload delivery, but requires sophisticated carrier design. Taking advantage of PPAA functionality, we have incorporated PPAA into PLGA MPs as a simple polymer mixture to enhance cytosolic delivery of PLGA-encapsulated payloads. Rhodamine loaded PLGA and PPAA/PLGA blend MPs were prepared by a modified nanoprecipitation method. Incorporation of PPAA into PLGA MPs had little to no effect on the size, shape, or loading efficiency, and evidenced no toxicity in Chinese hamster ovary epithelial cells. Notably, incorporation of PPAA into PLGA MPs enabled pH-dependent membrane disruption in a hemolysis assay, and a three-fold increased endosomal escape and cytosolic delivery in dendritic cells after 2 h of MP uptake. These results demonstrate that a simple PLGA/PPAA polymer blend is readily fabricated into composite MPs, enabling cytosolic delivery of an encapsulated payload. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 106A: 1022-1033, 2018.

show abstract

Poly (D,L-lactide-co-glycolide) nanoparticles: Uptake by epithelial cells and cytotoxicity

Cited by 16 publications

References 47 publications

Quantification of Oxaliplatin Encapsulated into PLGA Microspheres by TGA

Quantification of Oxaliplatin Encapsulated into PLGA Microspheres by TGA

Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin

Formulation and characterization of poly(propylacrylic acid)/poly(lactic‐co‐glycolic acid) blend microparticles for pH‐dependent membrane disruption and cytosolic delivery

Contact Info

Product

Resources

About